Newlunjie Biotech announced the completion of Series A financing. This Series A financing was led by Wuhan Optics Valley Science and Technology Innovation Industry Investment Fund Partnership (Limited...

In view of the biological complexity and treatment limitations of high-grade brain gliomas, NRG-103 injection is designed through the triple mechanism of quotin situ cell transdifferentiation + oncoly...

NRG-103 injection is an innovative product for the treatment of glioblastoma based on Nerenger's independently developed in situ transdifferentiation technology, also known as in vivo cell reprogrammi...

On August 11, 2025, Neulenge Biomedical Technology Co., Ltd., hereinafter referred to as Neulenge Biomedical Technology, announced that its independently developed world's first innovative drug NRG-10...

Recently, the first National Disruptive Technology Entrepreneurship Star List was officially released in Guangzhou. Newlunjie Biotech was successfully selected as the first National Disruptive Technol...

Neulenge NRG-103 is a new therapy for malignant glioma developed by Neulenge Biotech based on its independent intellectual property rights in situ transformation technology platform. On the basis of i...

After three months of fierce competition, Neulenge Biotech stood out from thousands of companies and won the first place in the Life and Health Track with its in-situ transformation technology! This c...

On December 16, 2024, the kick-off meeting of the clinical research project on the safety and effectiveness of NRG-103 injection in the treatment of patients with recurrent glioblastoma jointly carrie...